Michael Green

Michael Green, MD, PhD

Assistant Professor

VA Ann Arbor Healthcare System
2215 Fuller Rd
Ann Arbor, MI 48105

Clinical Contacts

VA Ann Arbor Healthcare System
Department of Radiation Oncology 2215 Fuller Rd Ann Arbor, MI 48105, Phone 734-845-3914

Administrative Contact

Kelley Coppola
734-936-7810

Biography

Dr. Green's overarching career focus is to advance cancer care by rationally integrating radiotherapy and immunotherapy.  His preclinical research platform focuses on designing the next generation of therapeutic strategies incorporating radiotherapy, targeted therapy, and immunotherapy. His translational research seeks define clinical and radiographic biomarkers of therapy efficacy. His clinical research aims to define the best ways to use radiotherapy and immunotherapy.

Areas of Interest

  • Radiobiology
  • Tumor immunology

Clinical Interests

  • Lung cancer
  • Liver cancer
  • Prostate cancer

Credentials

  • Residency, University of Michigan, Radiation Oncology 2019

Published Articles or Reviews

Most Recent (2019) Publications

  • Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. X Lang, MD Green, W Wang, J Yu, JE Choi, L Jiang, P Liao, J Zhou. Cancer discovery 9 (12), 1673-1685
  • Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response. C Grassberger, K Huber, NK Jacob, MD Green, P Mahler, J Prisciandaro. Journal of Applied Clinical Medical Physics 20 (10), 6
  • Functional Adaptation in Radiation Therapy. MM Matuszak, R Kashani, M Green, D Owen, S Jolly, M Mierzwa. Seminars in radiation oncology 29 (3), 236-244
  • CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. W Wang, M Green, JE Choi, M Gijón, PD Kennedy, JK Johnson, P Liao. Nature 569 (7755), 270
  • Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. LA Gharzai, MD Green, KA Griffith, T Else, CS Mayo, E Hesseltine. The Journal of Clinical Endocrinology & Metabolism
  • Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy. Q Zhang, MD Green, X Lang, J Lazarus, J Parsels, S Wei, LA Parsels. Cancer research, canres. 0761.2019

Web Sites

Locations
2215 Fuller Rd
Ann Arbor, MI 48105
800-361-8387
734-769-7100